MarketsandMarkets analysis says that a Potential Opportunity Worth $50 Bn is opening up in Genomics

As Genome Sequencing heads to $100 Direct-to-Consumer, a potential opportunity worth $50 Bn is expected to open up, leading to a million terabytes of genome data by 2025.

The genome sequencing market will reach $25 Bn by 2026, further intensified by COVID-19, and oncology and rare disease diagnostics coupled with pan genome studies. Adjacent markets of data storage, high performance computing (HPC), lab automation, and AI are anticipated to see unlocking of a further $20 Bn.

Download PDF Brochure: https://www.marketsandmarkets.com/practices/pdfdownload.asp

According to MarketsandMarkets analysis,

• $50 Bn of potential opportunity is opening up as genome sequencing heads to $100 direct-to-consumer, which was one of the most talked-about trends in 2021.
• The global genomic studies and projects comprising advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies.
• Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare, gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market.
• The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the demand for IVD over the next few years.

MarketsandMarkets is focused on high-growth, niche markets, such as AI in genomics, spatial genomics & transcriptomics, liquid biopsy, single-cell analysis, and related markets, providing a comprehensive understanding of the entire genomics ecosystem through the World’s First Market Intelligence Cloud, ‘KnowledgeStore’. It helps find blind spots in clients’ revenue decisions because of interconnections and unknowns that impacting clients and their client’s clients.

GROWTH PROBLEMS ENCOUNTERED BY GENOMICS COMPANIES

Customer prioritization and assessing unmet needs:

1. What are the disruptions in our clients' businesses? How can we support them for our own growth?
2. Who are the most potential customers going forward? Should we prioritize hospitals & clinics over research centers & academic centers or Pharmaceutical & Biotechnology companies?
3. What are the key unmet needs of customers? Who are the key stakeholders in different settings? Do vendor selection criteria differ by settings? Which new product features should be added to the existing products?

Where to Play:

1. Which applications and disease areas should we focus on? Should it be oncology, rare diseases, reproductive disorders or any other?
2. Which regions should we place our bets on? Should we continue with developed countries or do developing countries offer more growth opportunities?

Building a compelling Right to Win (RTW):

1. For M&A, which are the right targets for us? Should we target bioinformatics companies or consumables companies? Should we enter new markets directly or through partners?
2. How can we differentiate from top players? What is their right-to-win vs ours?

For more details, please visit: https://www.marketsandmarkets.com/practices/genomics-new.asp

Press Release: https://www.marketsandmarkets.com/PressReleases/genomics.asp

For more details, visit :https://www.marketsandmarkets.com/Market-Reports/radiation-dose-management-market-82326344.html